Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic benefit, and the synthesis of prodrugs of fluorouracil that are potentially more effective and less toxic. Of particular interest at present is the clinical evaluation of several new fluoropyrimidine drugs that can be orally administered. Thes include capecitabine, tegafur/uracil (UFT®), eniluracil (GW-776C85; 5-ethylnyl-uracil), S-1, and emitefur (BOF-A2). The pharmacological principles that have influenced the development of these new drugs are initially presented. This is followed by a review of our current knowledge of the clinical pharmacology of each of these new agents, focusing on antitumour activity and toxicity from studies conducted in the US. Studies of capecitabine, tegafur/uracil, and early studies with eniluracil indicate that these drugs have at least similar activity to protracted fluorouracil infusion but with additional quality-of-life and economic benefits.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalDrugs
Volume58
Issue numberSUPPL. 3
StatePublished - 1999
Externally publishedYes

Fingerprint

Chemotherapy
Fluorouracil
Uracil
Drug Therapy
Tegafur
Pharmaceutical Preparations
Clinical Pharmacology
Poisons
Prodrugs
Metabolism
Toxicity
Appointments and Schedules
Economics
Quality of Life
Modulation
Pharmacology
eniluracil

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. / Diasio, Robert B.

In: Drugs, Vol. 58, No. SUPPL. 3, 1999, p. 119-126.

Research output: Contribution to journalArticle

@article{ccaef61fcb9f497ea45f91979c7bac76,
title = "Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines",
abstract = "During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic benefit, and the synthesis of prodrugs of fluorouracil that are potentially more effective and less toxic. Of particular interest at present is the clinical evaluation of several new fluoropyrimidine drugs that can be orally administered. Thes include capecitabine, tegafur/uracil (UFT{\circledR}), eniluracil (GW-776C85; 5-ethylnyl-uracil), S-1, and emitefur (BOF-A2). The pharmacological principles that have influenced the development of these new drugs are initially presented. This is followed by a review of our current knowledge of the clinical pharmacology of each of these new agents, focusing on antitumour activity and toxicity from studies conducted in the US. Studies of capecitabine, tegafur/uracil, and early studies with eniluracil indicate that these drugs have at least similar activity to protracted fluorouracil infusion but with additional quality-of-life and economic benefits.",
author = "Diasio, {Robert B}",
year = "1999",
language = "English (US)",
volume = "58",
pages = "119--126",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines

AU - Diasio, Robert B

PY - 1999

Y1 - 1999

N2 - During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic benefit, and the synthesis of prodrugs of fluorouracil that are potentially more effective and less toxic. Of particular interest at present is the clinical evaluation of several new fluoropyrimidine drugs that can be orally administered. Thes include capecitabine, tegafur/uracil (UFT®), eniluracil (GW-776C85; 5-ethylnyl-uracil), S-1, and emitefur (BOF-A2). The pharmacological principles that have influenced the development of these new drugs are initially presented. This is followed by a review of our current knowledge of the clinical pharmacology of each of these new agents, focusing on antitumour activity and toxicity from studies conducted in the US. Studies of capecitabine, tegafur/uracil, and early studies with eniluracil indicate that these drugs have at least similar activity to protracted fluorouracil infusion but with additional quality-of-life and economic benefits.

AB - During the 40 years since the initial synthesis of fluorouracil, there have been many attempts to improve fluoropyrimidine chemotherapy. These have included the utilisation of different schedules of fluorouracil administration, modulation of the metabolism of fluorouracil with other drugs to increase its therapeutic benefit, and the synthesis of prodrugs of fluorouracil that are potentially more effective and less toxic. Of particular interest at present is the clinical evaluation of several new fluoropyrimidine drugs that can be orally administered. Thes include capecitabine, tegafur/uracil (UFT®), eniluracil (GW-776C85; 5-ethylnyl-uracil), S-1, and emitefur (BOF-A2). The pharmacological principles that have influenced the development of these new drugs are initially presented. This is followed by a review of our current knowledge of the clinical pharmacology of each of these new agents, focusing on antitumour activity and toxicity from studies conducted in the US. Studies of capecitabine, tegafur/uracil, and early studies with eniluracil indicate that these drugs have at least similar activity to protracted fluorouracil infusion but with additional quality-of-life and economic benefits.

UR - http://www.scopus.com/inward/record.url?scp=0033512792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033512792&partnerID=8YFLogxK

M3 - Article

C2 - 10711850

AN - SCOPUS:0033512792

VL - 58

SP - 119

EP - 126

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - SUPPL. 3

ER -